Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage

This is an phase III prospective, multi-center, open-label, randomized controlled trial (RCT) with blinded endpoint assessment. It plans to enroll 768 subjects with spontaneous supratentorial intracerebral hemorrhage, who will be randomly assigned in a 1:1 ratio to the investigational arm (stereotactic minimally invasive puncture for intracerebral hemorrhage combined with TNK liquefaction drainage, single TNK dose of 0.5mg per time or the standard medical treatment group.

NCT Number	NCT07208097
Lead Sponsor	Tongji Hospital
Conditions	Intracerebral Haemorrhage, Minimally Invasive Treatment
Enrollment	768 participants
Start Date	2025-10-25
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-01